Meeting
2024 ASCO Genitourinary Cancers Symposium
Optimal sequential therapy for metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors in the up-front era.
Authors
Yushi Naito
Department of Urology, Nagoya University Hospital, Nagoya, Japan
Yushi Naito , Jun Nagayama , Yuta Sano , Satoshi Inoue , Kazuna Matsuo , Tomoyasu Sano , Shohei Ishida , Yoshihisa Matsukawa , Masashi Kato , Shusuke Akamatsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 168)
DOI
10.1200/JCO.2024.42.4_suppl.168
Abstract #
168
Poster Bd #
G18
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
First Author: Gero Kramer
Poster
2021 Genitourinary Cancers Symposium
The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone-sensitive prostate cancer.
First Author: Justin Shaya
Poster
2020 Genitourinary Cancers Symposium
Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641.
First Author: Julie Nicole Graff
Poster
2017 Genitourinary Cancers Symposium
Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.
First Author: Simon Chowdhury